[논문]The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia

Agouridis, Aris P; Tsimihodimos, Vasilis; Filippatos, Theodosios D; Dimitriou, Andromachi A; Tellis, Costantinos C; Elisaf, Moses S; Mikhailidis, Dimitri P; Tselepis, Alexandros D

doi:10.1517/14656566.2011.591383

The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia

Expert opinion on pharmacotherapy, v.12 no.17, 2011년, pp.2605 - 2611

Agouridis, Aris P (University of Ioannina Medical School, Department of Internal Medicine, 45110 Ioannina, Greece) , Tsimihodimos, Vasilis , Filippatos, Theodosios D , Dimitriou, Andromachi A (University of Ioannina Medical School, Department of Internal Medicine, 45110 Ioannina, Greece) , Tellis, Costantinos C , Elisaf, Moses S , Mikhailidis, Dimitri P (University of Ioannina Medical School, Department of Internal Medicine, 45110 Ioannina, Greece) , Tselepis, Alexandros D

Abstract ▼ AI-Helper

Objective: Mixed dyslipidemia, oxidative stress and inflammation are related to a high risk for cardiovascular events. The aim of this open-label randomized study was to compare the effects of high-dose rosuvastatin, low-dose rosuvastatin plus fenofibrate and low-dose rosuvastatin plus omega 3 fatty acids on inflammation and oxidative stress indices in patients with mixed dyslipidemia.Methods: Ninety patients with mixed dyslipidemia participated in the study. Patients were randomly allocated to receive rosuvastatin 40 mg (n == 30, group R), rosuvastatin 10 mg plus fenofibrate 200 mg (n == 30, group RF) or rosuvastatin 10 mg plus omega 3 fatty acids 2 g daily (n == 30, group RΩ？？. Plasma and high-density lipoprotein (HDL)-associated lipoprotein-associated phospholipase A2 (LpPLA2) activities, high-sensitivity C reactive protein (hsCRP), plasma isoprostane and paraoxonase (PON1) activities were measured at baseline and after 3 months of treatment.Results: Serum concentrations of non-HDL cholesterol and low-density lipoprotein cholesterol (LDL-C) were significantly reduced in all study groups. However, these changes were more pronounced in the rosuvastatin monotherapy group. In all treatment groups a significant reduction in total plasma LpPLA2 activity was observed (by 41, 38 and 30% for groups R, RF and RΩ？？ respectively). This decrease was greater in the R and RF groups compared with the RΩ？？combination (p < 0.05). HDL-LpPLA2 activity was increased more in the RF group (++43%) compared with the R and RΩ？？groups (++ 18% and ++ 35%, respectively; p < 0.05 for both comparisons). In all treatment groups there was a nonsignificant reduction in plasma 8-iso-PGF2α levels. A 53% reduction of hsCRP levels was observed in the R group, while in the RF and RΩ？？groups the reduction was 28 and 23%, respectively (p < 0.05 and p < 0.01 for the comparisons of group R with groups RF and RΩ？？ respectively). No significant changes were observed in PON activities in all treatment groups.Conclusion: The greater non-HDL-C- and LDL-C-lowering efficiency of rosuvastatin monotherapy along with its more potent effect on LpPLA2 activity and hsCRP levels indicate that this regimen is a better treatment option for patients with mixed dyslipidemia.

주제어

참고문헌 (48)

JAMA Castelli WP 2835 12 1986 10.1001/jama.1986.03380200073024

상세보기
Arterioscler Thromb Vasc Biol Tselepis AD 1764 15 1995 10.1161/01.ATV.15.10.1764

상세보기
Tselepis, Alexandros D, John Chapman, M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis. Supplements, vol.3, no.4, 57-68.

상세보기
Lancet Thompson A 1536 375 2010 10.1016/S0140-6736(10)60319-4

상세보기
Tellis, C.C., Tselepis, A.D.. The role of lipoprotein-associated phospholipase A₂ in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochimica et biophysica acta, Molecular and cell biology of lipids, vol.1791, no.5, 327-338.

상세보기
Navab, Mohamad, Berliner, Judith A., Subbanagounder, Ganesamoorthy, Hama, Susan, Lusis, Aldons J., Castellani, Lawrence W., Reddy, Srinivasa, Shih, Diana, Shi, Weibin, Watson, Andrew D., Van Lenten, Brian J., Vora, Deven, Fogelman, Alan M.. HDL and the Inflammatory Response Induced by LDL-Derived Oxidized Phospholipids. Arteriosclerosis, thrombosis, and vascular biology, vol.21, no.4, 481-488.

상세보기
J Hypertens Dhalla NS 655 18 2000 10.1097/00004872-200018060-00002

상세보기
Free Radic Biol Med Davies SS 559 50 2011 10.1016/j.freeradbiomed.2010.11.023

상세보기
Tex Heart Inst J Ridker PM 384 32 2005
N Engl J Med Danesh J 1387 350 2004 10.1056/NEJMoa032804

상세보기
Curr Probl Cardiol Bassuk SS 439 29 2004
MACKNESS, M, ARROL, S, ABBOTT, C, DURRINGTON, P. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, vol.104, no.1, 129-135.

상세보기
Watson, A D, Berliner, J A, Hama, S Y, La Du, B N, Faull, K F, Fogelman, A M, Navab, M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.. The Journal of clinical investigation, vol.96, no.6, 2882-2891.

상세보기
Curr Pharm Des Petraki MP 3146 15 2009 10.2174/138161209789057977

상세보기
J Clin Invest Aviram M 1581 101 1998 10.1172/JCI1649

상세보기
Lancet Durrington P 717 362 2003 10.1016/S0140-6736(03)14234-1

상세보기
Agouridis, A. P., Tsimihodimos, V., Filippatos, T. D., Tselepis, A. D., Elisaf, M. S.. High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n‐3 Fatty Acids in Mixed Dyslipidemia. Lipids, vol.46, no.6, 521-528.

상세보기
Am J Kidney Dis Dounousi E 752 48 2006 10.1053/j.ajkd.2006.08.015

상세보기
Tsimihodimos, Vasilis, Karabina, Sonia-Athena P., Tambaki, Afroditi P., Bairaktari, Eleni, Goudevenos, John A., Chapman, M. John, Elisaf, Moses, Tselepis, Alexandros D.. Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB. Arteriosclerosis, thrombosis, and vascular biology, vol.22, no.2, 306-311.

상세보기
Tsimihodimos, Vasilis, Kakafika, Anna, Tambaki, Afroditi P., Bairaktari, Eleni, Chapman, M.John, Elisaf, Moses, Tselepis, Alexandros D.. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. Journal of lipid research, vol.44, no.5, 927-934.

상세보기
Eur J Nutr Pedersen MW 1 48 2009 10.1007/s00394-008-0758-z

상세보기
Packard, Chris J., O'Reilly, Denis S.J., Caslake, Muriel J., McMahon, Alex D., Ford, Ian, Cooney, Josephine, Macphee, Colin H., Suckling, Keith E., Krishna, Mala, Wilkinson, Francis E., Rumley, Ann, Docherty, Gillian, Burczak, John D., Lowe, Gordon D.O.. Lipoprotein-Associated Phospholipase A₂as an Independent Predictor of Coronary Heart Disease. The New England journal of medicine, vol.343, no.16, 1148-1155.

상세보기
Ballantyne, Christie M., Hoogeveen, Ron C., Bang, Heejung, Coresh, Josef, Folsom, Aaron R., Heiss, Gerardo, Sharrett, A. Richey. Lipoprotein-Associated Phospholipase A ₂ , High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, vol.109, no.7, 837-842.

상세보기
Koenig, Wolfgang, Khuseyinova, Natalie, Löwel, Hannelore, Trischler, Gerlinde, Meisinger, Christa. Lipoprotein-Associated Phospholipase A ₂ Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population : Results From the 14-Year Follow-Up of a Large Cohort From Southern Germany. Circulation, vol.110, no.14, 1903-1908.

상세보기
Oei, Hok-Hay S., van der Meer, Irene M., Hofman, Albert, Koudstaal, Peter J., Stijnen, Theo, Breteler, Monique M.B., Witteman, Jacqueline C.M.. Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke : The Rotterdam Study. Circulation, vol.111, no.5, 570-575.

상세보기
Brilakis, Emmanouil S., McConnell, Joseph P., Lennon, Ryan J., Elesber, Ahmad A., Meyer, Jeffrey G., Berger, Peter B.. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. European heart journal, vol.26, no.2, 137-144.

상세보기
Arterioscler Thromb Vasc Biol Iribarren C 216 25 2005 10.1161/01.ATV.0000148322.89911.44

상세보기
Mayo Clin Proc Garza CA 159 82 2007 10.1016/S0025-6196(11)60992-0

상세보기
Filippatos, T.D., Gazi, I.F., Liberopoulos, E.N., Athyros, V.G., Elisaf, M.S., Tselepis, A.D., Kiortsis, D.N.. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A₂ in obese patients with metabolic syndrome. Atherosclerosis, vol.193, no.2, 428-437.

상세보기
Ridker, Paul M, Cook, Nancy. Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores. Circulation, vol.109, no.16, 1955-1959.

상세보기
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. The Lancet, vol.375, no.9709, 132-140.

상세보기
Lancet Ridker PM 1175 373 2009 10.1016/S0140-6736(09)60447-5

상세보기
J Cardiovasc Pharmacol Ther Kostapanos MS 157 13 2008 10.1177/1074248408318628

상세보기
Curr Med Res Opin Karalis IK 2301 26 2010 10.1185/03007995.2010.509264

상세보기
Belfort, Renata, Berria, Rachele, Cornell, John, Cusi, Kenneth. Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome. The Journal of clinical endocrinology & metabolism, vol.95, no.2, 829-836.

상세보기
Derosa, Giuseppe, Maffioli, Pamela, Salvadeo, Sibilla A. T., Ferrari, Ilaria, Gravina, Alessia, Mereu, Roberto, Palumbo, Ilaria, D'angelo, Angela, Cicero, Arrigo F. G.. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Current medical research and opinion : CMRO, vol.25, no.8, 1973-1983.

상세보기
Basic Clin Pharmacol Toxicol Krysiak R 23 109 2011 10.1111/j.1742-7843.2011.00675.x

상세보기
J Int Med Res Zhao YT 1831 37 2009 10.1177/147323000903700619

상세보기
Free Radic Biol Med Roberts LJ 505 28 2000 10.1016/S0891-5849(99)00264-6

상세보기
Mol Aspects Med Griffiths HR 101 23 2002 10.1016/S0098-2997(02)00017-1

상세보기
Proc Natl Acad Sci USA Morrow JD 9383 87 1990 10.1073/pnas.87.23.9383

상세보기
Morrow, Jason D.. Quantification of Isoprostanes as Indices of Oxidant Stress and the Risk of Atherosclerosis in Humans. Arteriosclerosis, thrombosis, and vascular biology, vol.25, no.2, 279-286.

상세보기
Lu, Tse-Min, Ding, Yu-An, Leu, Hsin-Bang, Yin, Wei-Hsian, Sheu, Wayne Huey-Herng, Chu, Kai-Min. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. The American journal of cardiology, vol.94, no.2, 157-161.

상세보기
Atherosclerosis Dong Y 422 214 2011 10.1016/j.atherosclerosis.2010.11.022

상세보기
J Ren Nutr Ramezani M 196 21 2011 10.1053/j.jrn.2010.06.023

상세보기
J Nutr Nalsen C 1222 136 2006 10.1093/jn/136.5.1222

상세보기
Eur J Clin Invest Dullaart RP 200 39 2009 10.1111/j.1365-2362.2009.02090.x

상세보기
Bergheanu, S C, Van Tol, A, Dallinga-Thie, G M, Liem, A, Dunselman, P H J, Van der Bom, J G, Jukema, J W. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.. Current medical research and opinion : CMRO, vol.23, no.9, 2235-2240.

상세보기

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia

Abstract ▼ AI-Helper

주제어

참고문헌 (48)

이 논문을 인용한 문헌

관련 콘텐츠

원문 URL 링크

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트